12 / 24
PANCREOX trial
•
Phase III
•
Canadian, multicentre (12 centers), open-label trial
•
From May 2010 to December 2012 (2,5y)
•
108 patients with APC previously treated with
gemcitabine-based therapy
(monotherapy 75%)
•
mFOLFOX6 associated with more treatment-related Grade 3/4 AEs (63% vs 11%)
Study withdrawal due to disease progression
was observed more frequently in
the FU/LV arm (
75% v 55%
)
•
Withdrawal due to adverse events
was greater in the mFOLFOX6 arm (
20% v 2%
)
•
Post-progression therapy higher in FU/LV arm
(25% vs 7%, p .015)
Gill et al, J Clin Oncol 2016